



February 10, 2022

Perseus Proteomics Inc.

Securities Code: 4882 Mothers TSE

To all stakeholders,

Announcement of Agreement on Joint Research Regarding Development of Quick Detection Kit of  
Pentraxin3 in the Blood with Wakunaga Pharmaceutical

Perseus Proteomics Inc. is pleased to announce that the Company has signed an agreement on joint research regarding the development of products related to simple quantitative/qualitative analysis of pentraxin 3 (PTX3) in the blood with Wakunaga Pharmaceutical Co., Ltd (HQ: Shinjuku-ku, Tokyo, President & CEO: Kanji Wakunaga, hereinafter “Wakunaga”).

1. Background and outline of the contract

The Company has been providing “Human Pentraxin3/TSG-14 ELISA System,” an ELISA kit for research to determine the quantity of PTX3 density in culturing supernatant or human blood plasma for researchers and research institutes since 2008. PTX3 density is known to be high in diseases associated with inflammation including vascular disorder and heart diseases: PTX3 has been on the focus as a biomarker to determine exacerbation of diseases associated with inflammation as well as infectious diseases including COVID-19.

Wakunaga has achieved significant results in reagent/diagnosis business, including development of “WAKFlow<sup>®</sup> HLA Typing reagent,” a donor registration reagent officially adopted by Japan Marrow Donor Program, utilizing xMAP Technology and “Rapicheck<sup>®</sup> H-FABP,” an external body diagnosing drug for acute heart attack.

The purpose of this joint research is to launch easy-to-use PTX3 quantification reagents with higher accuracy than the exiting ELISA kits or PTX3 detectors, utilizing anti-human PTX3 antibody and knowledge on PTX3 of the Company and the detecting technology accumulated by Wakunaga. Wakunaga and the Company plan to develop external diagnosis drugs to prognosticate various cardiovascular diseases including sepsis in the future. Through enabling prognostication of diseases, the Company hopes to provide the appropriate treatment for patients at an early stage and contribute to reduction of doctors’ workload.

2. Future forecast

There is no impact on the business results of the fiscal year ending March 31, 2022.

[About PTX3]

PTX 3 is known as protein that exists in white blood cells and vascular endothelial cells and that is secreted locally at the inflammation area. It is also positioned as a receptor recognizing solubility pattern



of natural immune as it increases in the blood, binds to pathogen including viruses and opsonizes at the early stage of infection.

PTX3 is expected to be utilized as a biomarker which determines inflammation progress at an early stage as there are reports of its increase in the blood at the early stage of inflammation compared with CRP and SAP.

[About Wakunaga Pharmaceutical Co., Ltd.]

Since its establishment in 1955, Wakunaga has been developing, manufacturing and selling medical drugs and health supplements including “Kiyo Leopin” series, a long-selling nourishing tonic medicine. It is a company aiming to contribute to society through development of reagents and diagnostic agents utilizing its unique biotechnology and development of excellent products utilizing its drug discovery technology that enables creation of medical drug candidates. Please refer to the website for the details:

<http://www.wakunaga.co.jp/english/index.html>

[Contact]

Perseus Proteomics Inc.

Administrative Division Phone: +81-3-5738-1705 e-mail: [ir@ppmx.com](mailto:ir@ppmx.com)